Quotables
"The wireless music box has no imaginable commercial value. Who would pay for a message sent to nobody in particular?"
David Sarnoff, American radio pioneer ; 1921
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120107339 | Chimeric Factor H Binding Proteins (fHBP) Containing a Heterologous B Domain and Methods of Use Chimeric fHBPs that can elicit antibodies that are bactericidal for different fHBP variant strains of N. meningitidis, and methods of use, are provided.... | 05/03/2012 |
| 20120070458 | ADJUVANTING MENINGOCOCCAL FACTOR H BINDING PROTEIN Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal ... | 03/22/2012 |
| 20120052092 | VACCINE COMPOSITIONS COMPRISING A MUTATED FACTOR H BINDING PROTEIN The present invention relates to an immunogenic composition comprising at least one modified factor H binding protein, wherein the composition is capable of eliciting an immune response, when administered to a human or non-human animal; and associated compositions, uses... | 03/01/2012 |
| 20120027801 | POLYPEPTIDES FROM NEISSERIA MENINGITIDIS Various specific meningococcal proteins are disclosed. The invention provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine for treating or preventing disease and/or infection caused by meningococcus, such as bacterial me... | 02/02/2012 |
| 20120014991 | NOVEL, NON-ANTIGENIC, MUCOSAL ADJUVANT FORMULATION WHICH MODULATES THE EFFECTS OF SUBSTANCES, INCLUDING VACCINE ANTIGENS, IN CONTACT WITH MUCOSAL BODY SURFACES Adjuvant for mucosal vaccines which modulates the effects of substances, including vaccine antigens in contact with mucosal body surfaces.... | 01/19/2012 |
| 20110300171 | FACTOR H BINDING PROTEIN IMMUNOGENS The invention relates to immunization against pathogenic bacterial strains which express or can express multiple factor H binding proteins. Certain aspects of the invention include vaccine compositions comprising at least two factor H binding proteins derived from a pat... | 12/08/2011 |
| 20110262484 | OUTER MEMBRANE VESICLE PRIME-PROTEIN BOOST VACCINE The present invention provides a method of immunizing a subject against a disease caused by Neisseria meningitidis, comprising administering to the subject a primer composition comprising a meningococcal outer membrane vesicle preparation, and a booster compositi... | 10/27/2011 |
| 20110256180 | Factor H Binding Proteins (FHBP) with Altered Properties and Methods of Use Thereof Factor H binding proteins that can elicit antibodies that are bactericidal for at least one strain of N. meningitidis, and methods of use of such proteins, are provided.... | 10/20/2011 |
| 20110250223 | HYBRID AND TANDEM EXPRESSION OF NEISSERIAL PROTEINS Two or more Neisserial proteins are joined such that they are translated as a single polypeptide chain. Hybrid proteins are represented by the formula NH2-A-[-X-L-]n-B—COOH where X is an amino acid sequence, L is an optional linker amino acid seq... | 10/13/2011 |
| 20110229522 | METHODS, COMPOSITIONS AND VACCINES RELATING TO NEISSERIA MENINGITIDIS ANTIBODIES The invention provides compositions and methods for screening subjects at risk for contracting meningococcal disease and/or at risk for failing to elicit an immunogenic response to a vaccine against Neisseria meningitidis. The invention also provides kits for car... | 09/22/2011 |
| 20110189215 | Vaccine Comprising Protein NMB0964 From Neisseria Meningitidis The present invention relates to immunogenic compositions comprising neisserial blebs with upregulated levels of the NMB0964 antigens such that bacterial antibodies are generated against said antigen. Methods are also provided to upregulate expression through removal of... | 08/04/2011 |
| 20110171234 | Vaccine The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine comprising o | 07/14/2011 |
| 20110159030 | MUCOSAL COMBINATION VACCINES FOR BACTERIAL MENINGITIS A composition for mucosal delivery, comprising two or more of the following: (a) an antigen which induces an immune response against Haemophilus influenzae; (b) an antigen which induces an immune response against Neisseria meningitidis; and (c) an antigen ... | 06/30/2011 |
| 20110150923 | MUCOSAL MENINGOCOCCAL VACCINES The invention provides immunogenic compositions for mucosal delivery comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of N. meningitidis. It is preferred that the capsular saccharides in the compositions of the invention are conjug... | 06/23/2011 |
| 20110135679 | COMPOSITIONS FOR INDUCING IMMUNE RESPONSES The invention provides, inter alia, immunogenic compositions that comprise (a) a first antigen, (b) at least first and second adjuvants, wherein the first adjuvant comprises microparticles and wherein the second adjuvant comprises an imidazoquinoline compound, and (c) a... | 06/09/2011 |
| 20110111017 | USE OF IMMUNOGENIC COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF PATHOGEN INFECTIONS The invention provides compositions featuring cationic liposome nucleic acid molecules complexed with pathogen derived antigen and methods of using such compositions for the treatment or prevention of an infectious disease. Other features and advantages of the invention... | 05/12/2011 |
| 20110033491 | MULTICOMPONENT MENINGOCOCCAL VACCINE A composition is provided comprising N. meningitidis outer membrane vesicles, wherein said outer membrane vesicles are enriched with at least one antigenic component. The composition is suitable for use in vaccines and for treatment of infection, particularly men... | 02/10/2011 |
| 20110033500 | VACCINE COMPOSITIONS COMPRISING L2 AND/OR L3 IMMUNOTYPE LIPOOLIGOSACCHARIDES FROM LGTB-NEISSERIA MENINGITIDIS The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the pro... | 02/10/2011 |
| 20110020390 | MENINGOCOCCAL FHBP POLYPEPTIDES fHBP is a protein in Neisseria meningitidis. Three families of fHBP are known. To increase the ability of a fHBP protein to elicit antibodies that are cross-reactive between the families, fHBP is selected or engineered to have a sequence which can elicit broad-sp... | 01/27/2011 |
| 20110014272 | Method for adjuvanting lipopolysaccharide (LPS) of Gram-negative bacteria The subject of the invention is a method for adjuvanting LPS of a Gram-negative bacterium, according to which LPS or LPS liposomes (LPS formulated in liposomes) is (are) mixed with the lipidated human-transferrin receptor subunit B (TbpB protein) of Neisseria meningi... | 01/20/2011 |
| 20110014226 | HIGH THROUGHPUT PROTEIN INTERACTION ASSAY A method to identify small molecules useful as therapeutics and/or vaccines to prevent, alleviate or ameliorate a pathogenic infection or an autoimmune disorder. The method can be used to screen small molecule test compounds for the ability to disrupt particular antigen... | 01/20/2011 |
| 20100322958 | MODIFIED SACCHARIDES Modified capsular saccharides comprising a blocking group at a hydroxyl group position on at least one of the monosaccharide units of the corresponding native capsular saccharide, wherein the blocking group is of the formula (Ia) or (Ib): —OX—Y (Ia) or —O—R... | 12/23/2010 |
| 20100291137 | METHOD FOR REFOLDING NEISSERIAL NSPA PROTEIN The present invention provides an isolated refolded NspA protein, and a method of preparing it.... | 11/18/2010 |
| 20100285064 | ADJUVANT COMPOSITION FOR VACCINE The present invention provides a Withania somnifera fraction rich in withanolides and a vaccine comprising a “Withania somnifera fraction” as an adjuvant.... | 11/11/2010 |
| 20100285069 | MENINGOCOCCAL VACCINE FORMULATIONS A dual formulation for vaccines against Neisseria meningitidis serogroup B (‘Men-B’) comprises (i) an oil-in-water emulsion adjuvant and (ii) a Men-B immunogenic component in lyophilised form. The lyophilised Men-B antigens can be reconstituted into liquid ad... | 11/11/2010 |
| 20100272725 | Neisserial antigens The invention provides proteins from Neisseria meningitidis (strains A & B) and from Neisseria gonorrhoeae, including amino acid sequences, the corresponding nucleotide sequences, expression data, and serological data. The proteins are useful antigens ... | 10/28/2010 |
| 20100239607 | COMPOSITIONS FOR INDUCING IMMUNE RESPONSES The invention provides, inter alia, immunogenic compositions comprising a first antigen, at least two adjuvants, wherein a first adjuvant comprises a polymer derived from poly(lactides) and/or poly(lactide-co-glycolides), and wherein a second adjuvant comprises an imida... | 09/23/2010 |
| 20100203057 | NOVEL COMPOUNDS The invention provides BASB047, BASB054, BASB068 and BASB069 polypeptides, and polynucleotides encoding BASB047, BASB054, BASB068 and BASB069 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic a... | 08/12/2010 |
| 20100189737 | Meningococcal vaccines including hemoglobin receptor The meningococcal haemoglobin receptor, HmbR, is used as a vaccine antigen in combination with one or more further antigens e.g. in combination with a meningococcal outer membrane vesicle, with another purified meningococcal antigen (e.g. fHBP, 287, NadA, NspA, NhhA, Ap... | 07/29/2010 |
| 20100143418 | Immunising Against Meningococcal Serogroup Y Using Proteins The invention uses polypeptide antigens and/or OMVs to immunize against serogroups A, C, W135 and Y (and against serogroup Y in particular). Serogroup B polypeptides can achieve this protection, thus permitting a single polypeptide-based vaccine to be used for pr... | 06/10/2010 |
| 20100136043 | COMPOSITION COMPRISING IMMUNOGENIC MICROPARTICLES The invention provides an immunogenic composition comprising at least one antigen in association with micropar-tides, wherein the microparticles are in the same size range as viruses. In addition the invention also provides vaccine compositions and methods of eliciting ... | 06/03/2010 |
| 20100092509 | Hypo- and Hyper- Acetylated Meningococcal Capsular Saccharides Capsular saccharides derived from serogroups W135 and Y of Neisseria meningitidis have altered levels of O-acetylation at the 7 and 9 positions of their sialic acid residues, and can be used to make immunogenic compositions. Relative to unmodifed native saccharid... | 04/15/2010 |
| 20100092519 | COMPOSITIONS COMPRISING POLYSACCHARIDE CONJUGATES AND THEIR USE AS VACCINES The present invention is in the field of combination therapies, including vaccine compositions, which comprise polysaccharide-protein conjugates and outer membrane vesicles (OMVs) from commensal bacteria, particularly commensal Neisseria. ... | 04/15/2010 |
| 20100055129 | MODULATORS OF MYC, METHODS OF USING THE SAME, AND METHODS OF INDENTIFIYING AGENTS THAT MODULATE MYC Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune respons... | 03/04/2010 |
| 20100015175 | Vaccine The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine including one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treati... | 01/21/2010 |
| 20100003283 | LIPID A DEFICIENT MUTANTS OF NEISSERIA MENINGITIDIS The invention provides lipid A deficient mutant Neisseria meningitidis cells, pharmaceutical compositions incorporating such cells, and methods of using such cells.... | 01/07/2010 |
| 20100003280 | Adjuvant compositions Adjuvant compositions comprising type 1 interferon inducers, such as double-stranded RNA, in combination with antigen delivery systems and/or immunostimulatory molecules, such as immunostimulatory nucleic acid sequences, for enhancing the immune response of a coadminist... | 01/07/2010 |
| 20090304743 | Composition and Methods for Immunisation Using CD1D Ligands The invention relates to immunogenic compositions containing CD1d ligands that induce long-term immunological memory in the absence of booster doses and/or in the absence of multiple priming doses. The invention further relates to immunogenic compositions containing CD1... | 12/10/2009 |
| 20090246224 | VACCINE The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the pro... | 10/01/2009 |
| 20090214537 | Serum Resistance Factors of Gram Positive Bacteria A newly identified serum resistance factor of gram positive bacteria can be used to treat or prevent bacterial infection.... | 08/27/2009 |
